Akorn, Inc. (NASDAQ:AKRX)

CAPS Rating: 3 out of 5

The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.

Results 1 - 20 of 26 : 1 2 Next »

Recs

0
Member Avatar racoveanul (80.40) Submitted: 4/12/2014 3:33:34 PM : Outperform Start Price: $21.77 AKRX Score: +51.64

My 1y target for Akorn, Inc. (Symbol: AKRX) is $ 26.63. It implies an increase of 23.68% of the share price (April 11 2014).

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/10/2014 8:38:49 PM : Outperform Start Price: $21.99 AKRX Score: +51.86

EPS 1YR 40% 2YR 35% 5YR 20%

Recs

0
Member Avatar TerryHoodSr (43.15) Submitted: 3/7/2014 7:29:08 PM : Outperform Start Price: $21.99 AKRX Score: +51.86

BUY@ 22 TP 27 EPS GROWTH: 1YR 43% 2YR 35% 5YR 52%

Recs

0
Member Avatar tedski2000 (< 20) Submitted: 10/29/2013 2:19:00 PM : Outperform Start Price: $20.85 AKRX Score: +55.02

This stock was on the Zacks list of #1 Rank Additions on the day it was placed in the CAPS portfolio.

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:12:18 PM : Outperform Start Price: $13.53 AKRX Score: +140.32

Long. Pharma. PE 34x ttm 17x fye. $1.3B mkt cap. 42% Rev growth, 248% E growth.

Recs

0
Member Avatar claricecliff (< 20) Submitted: 8/6/2012 12:44:01 PM : Outperform Start Price: $13.65 AKRX Score: +113.54

I don't think the analysts are aware of the scope of the generic market. Some are saying (Deutsche) that Akorn will not manufacture enough generics? How do they know when the FDA is not working with DEA to know what's in the pipeline or which drugs will be approved?

Recs

0
Member Avatar cobradon (99.21) Submitted: 2/1/2012 6:05:44 PM : Outperform Start Price: $3.32 AKRX Score: +858.55

I saw one of the rating agencies tout this as a raging buy.... But, beyond that I like the whole pharma section as the baby boomers become in need.

Recs

0
Member Avatar NuclearSteve (69.15) Submitted: 12/28/2011 2:26:56 PM : Outperform Start Price: $11.22 AKRX Score: +151.63

Following this for awhile. Bullish biotech from my own screens and the StockTwits50.

Recs

0
Member Avatar modestus1 (< 20) Submitted: 11/1/2011 11:59:33 PM : Outperform Start Price: $9.93 AKRX Score: +190.20

generics

Recs

0
Member Avatar Liquidman21 (< 20) Submitted: 9/25/2011 2:20:52 AM : Outperform Start Price: $8.13 AKRX Score: +256.92

Generic alternative drugs are the future. This is a sure fire pick!

Recs

0
Member Avatar kdzfool (< 20) Submitted: 9/24/2011 1:11:05 AM : Outperform Start Price: $9.07 AKRX Score: +210.52



Feel management is getting all cylinders operating properly. Paying more attention to details in compliance with fda and atf watchdogs, obtaining more profitable products and being the sole supplier of some, while controling dept properly.

Recs

0
Member Avatar elcheapo2020 (53.98) Submitted: 9/22/2011 12:57:04 PM : Outperform Start Price: $7.82 AKRX Score: +271.30

This company is currently experiencing high returns, high margins, a reasonable P/E, low debt, and good revenue growth. Today the market is getting slammed and is down around 400 points, and even though this stock has pulled back slightly today, it looks as if the market is dragging it down, not it's fundamentals.

This stock is a very long buy, particularly because of the way it's holding up today vs. the rest of the market. Very resistent on a bad down day. Right now it's under $9/share, but give it another year or two, and it'll be in the mid to upper teens, provided the numbers remain constant.

If not buying, at least add it to your watched list.

Recs

0
Member Avatar umeng78 (< 20) Submitted: 5/18/2011 11:33:19 PM : Outperform Start Price: $6.94 AKRX Score: +353.61

new high

Recs

2
Member Avatar HealthcareGuy (99.47) Submitted: 12/29/2010 4:44:02 PM : Outperform Start Price: $5.39 AKRX Score: +477.33

Akorn, is a generic pharma company that has been remade by successful healthcare turnaround investor John Kapoor (Chariman of the Board). The major catalyst for this name, will be FDA approval of AKRX’s generic version of Vancocin (first to file, been in FDA limbo for many years). Even branded Vanco manufacturer, Viropharma, has hinted that they believe 2011 will be the year they finally lose their vanco monopoly, which will probably send AKRX to the $12 range (assuming they receive a 6 month exclusivity)

Recs

0
Member Avatar RXDOC73 (99.31) Submitted: 12/16/2010 8:16:41 AM : Outperform Start Price: $6.04 AKRX Score: +415.57

Small and growing stronger

Recs

0
Member Avatar yoyoguy (< 20) Submitted: 6/8/2010 6:25:34 PM : Outperform Start Price: $2.85 AKRX Score: +1,033.19

Good looking upward market trend, despite occasional falls during market frenzies.

Recs

0
Member Avatar JOSEFB (< 20) Submitted: 5/5/2010 12:34:42 PM : Outperform Start Price: $2.84 AKRX Score: +1,054.67

Great cash position and products

Recs

0
Member Avatar Cruzera (< 20) Submitted: 4/21/2010 9:34:23 PM : Outperform Start Price: $2.05 AKRX Score: +1,527.32

The market has had a good run and investers are looking for innovation. Medical breakouts are a good place to hunt for cheap stocks. Acorn will continue to out do the market.

Recs

0
Member Avatar predfern (68.77) Submitted: 1/29/2009 12:17:17 AM : Outperform Start Price: $2.49 AKRX Score: +1,160.06

Jim Oberweis pick.
http://www.forbes.com/2009/01/28/hospital-medicine-intravenous-personal-finance-investing-ideas_0128_diptheria_tetanus.html?partner=biotech_newsletter

Tetanus Diphtheria vaccine has 25% market share and 3rd quarter sales increased 102%

New Product Development
FDA approved two generic antibiotics from joint venture with Strides Arcolab.
FDA approved opthalmic solution to treat corneal ulcers and conjunctivitis infections.
Akten Gel, a premium opthalmic anesthetic, was launched in october 2008 and is used for a variety of ocular procedures.

Recs

0
Member Avatar Hybr1d1nevstor (97.53) Submitted: 5/15/2008 11:56:31 PM : Outperform Start Price: $4.42 AKRX Score: +641.57

Akorn is starting to get their name out there more an is currently in the works of a few brand name products. Although they do not mnfr. their own products they have well established companies that do. I work for a pharmaceutical distributor and we are starting to sell their new Tetanus Diptheria. According to an inservice we just had with Akorn they plan to keep their Tetanus Diptheria always priced lower than its competitor. Just hitting a 52 week low today and bouncing back already this stock I think will double by the end of 2008 and will go higher long term.

Results 1 - 20 of 26 : 1 2 Next »

Featured Broker Partners


Advertisement